Drug Trial Radar · NCT07209111
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Apr 9, 2032
Study completion Apr 9, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Conditions
- Neoplasm Malignant
Interventions
CalderasibDrug
Oral administration
CetuximabBiological
Intravenous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to approximately 76 months
- Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 76 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 76 months
Locations
72 sites in 19 countries. Site status is shown where the registry gives one.
Greater Baltimore Medical Center ( Site 1104)
Baltimore, Maryland · Recruiting
START Midwest ( Site 1103)
Grand Rapids, Michigan · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 1109)
Las Vegas, Nevada · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 1100)
New Brunswick, New Jersey · Recruiting
START Mountain Region ( Site 1106)
West Valley City, Utah · Recruiting
Virginia Cancer Specialists ( Site 1102)
Fairfax, Virginia · Recruiting
Prince of Wales Hospital-Medical Oncology ( Site 1003)
Randwick, New South Wales, Australia · Recruiting
Westmead Hospital ( Site 1000)
Westmead, New South Wales, Australia · Recruiting
Epworth Freemasons ( Site 1004)
Melbourne, Victoria, Australia · Recruiting
The Ottawa Hospital ( Site 2902)
Ottawa, Ontario, Canada · Recruiting
Jewish General Hospital-CRU ( Site 2900)
Montreal, Quebec, Canada · Recruiting
Fundación Arturo López Pérez ( Site 1200)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Oncología de Precisión ( Site 1202)
Santiago, Region M. de Santiago, Chile · Recruiting
Clinica San Carlos de Apoquindo ( Site 1203)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 1201)
Santiago, Region M. de Santiago, Chile · Recruiting
Beijing Cancer hospital ( Site 1318)
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Xiamen University ( Site 1304)
Xiamen, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center ( Site 1303)
Guangzhou, Guangdong, China · Recruiting
The first affiliated hospital, Sun Yat-Sen university ( Site 1329)
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital ( Site 1308)
Harbin, Heilongjiang, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1326)
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital ( Site 1321)
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital ( Site 1322)
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital ( Site 1324)
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University ( Site 1307)
Nanchang, Jiangxi, China · Recruiting
Jinan Central Hospital ( Site 1313)
Jinan, Shandong, China · Recruiting
Shanghai Chest Hospital ( Site 1300)
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Shanghai Cancer Center ( Site 1325)
Shanghai, Shanghai Municipality, China · Recruiting
Zhongshan Hospital,Fudan University ( Site 1301)
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Cancer Hospital ( Site 1311)
Hangzhou, Zhejiang, China · Recruiting
Taizhou Hospital of Zhejiang Province ( Site 1312)
Linhai, Zhejiang, China · Recruiting
Rigshospitalet ( Site 1403)
Copenhagen, Capital Region, Denmark · Recruiting
Odense Universitetshospital ( Site 1401)
Odense, Region Syddanmark, Denmark · Recruiting
Hopital Pitie Salpetriere ( Site 1500)
Paris, France · Recruiting
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1503)
Limoges, Haute-Vienne, France · Recruiting
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1604)
Berlin, Germany · Recruiting
Universitätsklinikum Leipzig ( Site 1602)
Leipzig, Saxony, Germany · Recruiting
Universitätsklinikum Jena ( Site 1603)
Jena, Thuringia, Germany · Recruiting
European Interbalkan Medical Center-Oncology Department ( Site 1700)
Thessaloniki, Greece · Recruiting
General Hospital of Athens "Laiko" ( Site 1701)
Athens, Attica, Greece · Recruiting
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.